Molly Monsour

Molly Monsour


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
MMMolly Monsour
Molly Monsour
JGJonah Gordon
Jonah Gordon
GLGavin Miles Lockard
Gavin Miles Lockard
AAAdam Alayli
Adam Alayli
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Despite a relatively developed understanding of the pathophysiology underlying primary and secondary mechanisms of cell death after ischemic injury, there are few established treatments to improve stroke prognoses. A major contributor to secondary cell death is mitochondrial dysfunction. Recent advancements in cell-based therapies suggest that stem cells may be revolutionary for treating stroke, and the reestablishment of mitochondrial integrity may underlie these therapeutic benefits. In fact, functioning mitochondria are imperative for reducing oxidative damage and neuroinflammation following stroke and reperfusion injury. In this review, we will discuss the role of mitochondria in establishing the anti-oxidative effects of stem cell therapies for stroke.

31 August 2022 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
MMMolly Monsour
Molly Monsour
DCDavide Croci
Davide Croci
Basil Erwin GrüterBasil Erwin Grüter
Basil Erwin Grüter
Phillip TauskeyPhillip Tauskey
Phillip Tauskey
SMSerge Marbacher
Serge Marbacher
SASiviero Agazzi
Siviero Agazzi

Verified
Journal Article
Open access
PDF file
GLGavin Miles Lockard
Gavin Miles Lockard
AAAdam Alayli
Adam Alayli
MMMolly Monsour
Molly Monsour
JGJonah Gordon
Jonah Gordon
SSSamantha Schimmel
Samantha Schimmel
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Stem cell transplantation is historically understood as a powerful preclinical therapeutic following stroke models. Current clinical strategies including clot busting/retrieval are limited by their time windows (tissue plasminogen activator: 3–4 h) and inevitable reperfusion injuries. However, 24+ h post-stroke, stem cells reduce infarction size, improve neurobehavioral performance, and reduce inflammatory agents including interleukins. Typically, interleukin-6 (IL-6) is regarded as proinflammatory, and thus, preclinical studies often discuss it as beneficial for neurological recuperation when stem cells reduce IL-6′s expression. However, some studies have also demonstrated neurological benefit with upregulation of IL-6 or preconditioning of stem cells with IL-6. This review specifically focuses on stem cells and IL-6, and their occasionally disparate, occasionally synergistic roles in the setting of ischemic cerebrovascular insults.

Verified
Journal Article
Open access
PDF file
JGJonah Gordon
Jonah Gordon
GLGavin Miles Lockard
Gavin Miles Lockard
MMMolly Monsour
Molly Monsour
AAAdam Alayli
Adam Alayli
HCHassan Choudhary
Hassan Choudhary
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Parkinson’s disease is the second most common neurodegenerative disease. Insidious and progressive, this disorder is secondary to the gradual loss of dopaminergic signaling and worsening neuroinflammation, affecting patients’ motor capabilities. Gold standard treatment includes exogenous dopamine therapy in the form of levodopa–carbidopa, or surgical intervention with a deep brain stimulator to the subcortical basal ganglia. Unfortunately, these therapies may ironically exacerbate the already pro-inflammatory environment. An alternative approach may involve cell-based therapies. Cell-based therapies, whether endogenous or exogenous, often have anti-inflammatory properties. Alternative strategies, such as exercise and diet modifications, also appear to play a significant role in facilitating endogenous and exogenous stem cells to induce an anti-inflammatory response, and thus are of unique interest to neuroinflammatory conditions including Parkinson’s disease. Treating patients with current gold standard therapeutics and adding adjuvant stem cell therapy, alongside the aforementioned lifestyle modifications, may ideally sequester inflammation and thus halt neurodegeneration.

26 July 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
JGJonah Gordon
Jonah Gordon
GLGavin Miles Lockard
Gavin Miles Lockard
MMMolly Monsour
Molly Monsour
AAAdam Alayli
Adam Alayli
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Despite the reality that a death from cerebrovascular accident occurs every 3.5 min in the United States, there are few therapeutic options which are typically limited to a narrow window of opportunity in time for damage mitigation and recovery. Novel therapies have targeted pathological processes secondary to the initial insult, such as oxidative damage and peripheral inflammation. One of the greatest challenges to therapy is the frequently permanent damage within the CNS, attributed to a lack of sufficient neurogenesis. Thus, recent use of cell-based therapies for stroke have shown promising results. Unfortunately, stroke-induced inflammatory and oxidative damage limit the therapeutic potential of these stem cells. Nuclear factor erythroid 2-related factor 2 (Nrf2) has been implicated in endogenous antioxidant and anti-inflammatory activity, thus presenting an attractive target for novel therapeutics to enhance stem cell therapy and promote neurogenesis. This review assesses the current literature on the concomitant use of stem cell therapy and Nrf2 targeting via pharmaceutical and natural agents, highlighting the need to elucidate both upstream and downstream pathways in optimizing Nrf2 treatments in the setting of cerebrovascular disease.

Verified
Journal Article
Open access
PDF file
MMMolly Monsour
Molly Monsour
JGJonah Gordon
Jonah Gordon
GLGavin Miles Lockard
Gavin Miles Lockard
AAAdam Alayli
Adam Alayli
BEBassel Elsayed
Bassel Elsayed
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Epigenetic changes in stroke may revolutionize cell-based therapies aimed at reducing ischemic stroke risk and damage. Epigenetic changes are a novel therapeutic target due to their specificity and potential for reversal. Possible targets for epigenetic modification include DNA methylation and demethylation, post-translational histone modification, and the actions of non-coding RNAs such as microRNAs. Many of these epigenetic modifications have been reported to modulate atherosclerosis development and progression, ultimately contributing to stroke pathogenesis. Furthermore, epigenetics may play a major role in inflammatory responses following stroke. Stem cells for stroke have demonstrated safety in clinical trials for stroke and show therapeutic benefit in pre-clinical studies. The efficacy of these cell-based interventions may be amplified with adjunctive epigenetic modifications. This review advances the role of epigenetics in atherosclerosis and inflammation in the context of stroke, followed by a discussion on current stem cell studies modulating epigenetics to ameliorate stroke damage.